Session: SUN 459-496-Thyroid Neoplasia & Case Reports
Poster Board SUN-488
Authors: Pozniak,Silvina; Ilera, Veronica; Maffei,Laura Elena; Rojkind,Ana; Premrou, Maria Valeria
Consultorios Asociados de Endocrinología, Buenos Aires, Argentina
Introduction: Radioactive iodine (131-I) is used for the treatment and follow-up of differentiated thyroid cancer (DTC)in patients. 131-I is taken up by the salivary and lacrimal glands among others. Adverse events (AE) have been described in these organs secondary to the use of 131-I.
Objective: To analyze the frequency of AE in the oropharynx, salivary and lacrimal glands in patients with DTC who received I 131.
Material and methods: We retrospectively analyzed patients diagnosed with DTC and treated at a private endocrinology center of Buenos Aires and surveyed by telephone about EA. We included patients with one or more follow-up scans after ablative dose and analyzed the correlation between the AE, the 131-I dose and clinical-pathological variables.
Results: We analyzed 129 patients , an average age of 45.43 years (19-86 years), 103 women (79.8%) and 26 men (20.2%).
127 patients (98.2%) had papillary thyroid carcinoma, follicular Ca-two patients (1.65%)
EA in 32 patients (24.8%). Among these patients AE observed : parotid pain in 2 patients, parotid swelling and enlargement in 15, submaxillary gland swelling 2 and parotid lithiasis 1. Also reported xerostomia 18, dysgeusia 11,tooth decay 2 and xerophthalmia in 7.
The correlation between the frequency of EAS with the following variables were analyzed:
- Pathology, all patients had papillary carcinoma type
- Cumulative dose received, patients with AE (EA+) had a mean dose of 194,83 mCi vs patient without EA (EA-) 156,2 p = NS (0.14)
- Ablative dose received, average dose 140.32 mCi for EA+ and 120 forAE-, p = S (0.03)
- Whole body scan dose, average dose EA + 3,10 mCi vs EA- 2,80 mCi, p = NS (0.50)
- Age, EA + 40,69 years, and the EAS- 46,99, p = S (0.04)
- TNM, Low grade EAS + 31% and 20% in high grade, p = NS (0.33)
Conclusions: The prevalence of AE in our population was 24.8%, similar to that described in the literature. Among those who had a higher incidence of EA after ablative dose were higher and younger patients, both variables showing statistically significant data. And we observed a greater tendency of EA with higher cumulative doses received and in patients with low-grade thyroid carcinomas. These results together with the new guidelines for DTC treatment and follow-up reinforce the need to carefully assess the use of I131 in patients with low grade thyroid carcinomas and young people to avoid AE.
Nothing to Disclose: SRP, VI, LEM, AR, MVP
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters